Abstract
Background Amyotrophic lateral sclerosis (ALS) is a multifactorial, multisystem motor neuron disease for which currently there is no effective treatment. There is an urgent need to identify biomarkers to tackle the disease’s complexity and help in early diagnosis, prognosis, and therapy. Extracellular vesicles (EVs) are nanostructures released by any cell type into body fluids. Their biophysical and biochemical characteristics vary with the parent cell’s physiological and pathological state and make them an attractive source of multidimensional data for patient classification and stratification.
Methods We analyzed plasma-derived EVs of ALS patients (n= 106) and controls (n=96), and SOD1G93A and TDP-43Q331K mouse models of ALS. We purified plasma EVs by nickel-based isolation, characterized their EV size distribution and morphology respectively by nanotracking analysis and transmission electron microscopy, and analyzed EV markers and protein cargos by Western blot and proteomics. We used machine learning techniques to predict diagnosis and prognosis.
Results Our procedure resulted in high-yield isolation of intact and polydisperse plasma EVs, with minimal lipoprotein contamination. There were more particles in the plasma of ALS patients and the two mouse models of ALS while their average diameter was smaller. HSP90 was differentially represented in ALS patients and mice compared to the controls. In terms of disease progression, the levels of cyclophilin A, with the EV size distribution, distinguished fast and slow disease progressors, suggesting a new means for patient stratification. We also measured the levels of phosphorylated TDP-43 and showed that is not an intravesicular cargo of plasma-derived EVs.
Conclusions Our analysis unmasked features in plasma EVs of ALS patients with potential straightforward clinical application. We conceived an innovative mathematical model based on machine learning which, by integrating EV size distribution data with protein cargoes, gave very high prediction rates for disease diagnosis and prognosis.
Competing Interest Statement
VDA and AQ declare competing interests for the patent application of the NBI procedure (WO2019122003).
Funding Statement
This study has been supported by grants listed in the relative paragraph of the text
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All experiments have been conducted upon approval.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
laura.pasetto{at}marionegri.it, callegarostefano{at}gmail.com, deborah.ferrara{at}unitn.it>, laura.brunelli{at}marionegri.it, giovanna.sestito{at}marionegri.it, roberta.pastorelli{at}marionegri.it, elisa.bianchi{at}marionegri.it, alessandro.corbelli{at}marionegri.it, fabio.fiordaliso{at}marionegri.it, marina.cretich{at}cnr.it, marcella.chiari{at}cnr.it, cpotrich{at}fbk.eu, cristina.moglia{at}unito.it, m.corbo{at}ccppdezza.it, gianni.soraru{at}unipd.it, christian.lunetta{at}centrocliniconemo.it, andrea.calvo{at}unito.it, adriano.chio{at}unito.it, gabriele.mora{at}icsmaugeri.it, maria.pennuto{at}unipd.it, alessandro.quattrone{at}unitn.it, rinaldi{at}math.unipd.it, vito.dagostino{at}unitn.it, manuela.basso{at}unitn.it, valentina.bonetto{at}marionegri.it
Data Availability
Data availability All the data generated for this manuscript are available upon requests to the corresponding authors. Proteomics The whole mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium (http://proteomecentral.proteomexchange.org/cgi/GetDataset) via the PRIDE partner repository with the data set identifier PXD020629
Abbreviations
- ALS
- Amyotrophic lateral sclerosis
- AUC
- area under the curve
- CNS
- central nervous system
- CSF
- cerebrospinal fluid
- EVs
- Extracellular vesicles
- FTLD
- Frontotemporal lobar degeneration
- HC
- Healthy controls
- HSP90
- Heat shock protein-90
- MD
- Muscular dystrophies
- NTA
- Nanotracking analysis
- NBI
- Nickel-based isolation
- PBMCs
- peripheral blood mononuclear cells
- PPIA
- peptidyl-prolyl cis-trans isomerase A
- pNFH
- phosphorylated neurofilament heavy chain
- SBMA
- Spinal and bulbar muscle atrophy
- SOD1
- Superoxide dismutase 1
- TEM
- Transmission electron microscopy
- TRPS
- Tunable resistive pulse sensing
- UC
- Ultracentrifugation
- WB
- Western blot